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ÖZET
Amaç: Diyabetik polinöropati diabetin en ciddi bir komp-
likasyonudur ve dünyada en yaygın olan nöropatidir. Ak-
şamsefası yağı (EPO) omega-6 esansiyel yağ asit ve gama-
linoleik asit bakımından zengindir. Alfa lipoik asit (ALPA) 
lipid peroksidasyonuna karşı koruyucu bir etkiye sahiptir 
ve serbest oksijen radikallerini temizlemeye yardımcı olur. 
EPO tedavisinin diyabet parametreleri ve nöropatik belir-
tileri üzerine etkisi konusundaki veriler çelişkilidir. Bu çalış-
ma EPO ve ALPA’nın, streptozotosinle diyabet geliştirilen 
ratlarda, diyabetik parametreleri ve fonksiyonel ve yapısal 
nöropatik belirtileri düzeltmedeki tedavi etkinliğini belir-
lemeyi amaçlamıştır.
Gereç ve yöntem: Bu çalışmada EPO ile iki haftalık oral 
tedavi (1.25 g/kg) ALPA (100 mg/kg) ve insülin (2 U/gün) 
ile tek başına ve kombinasyon şeklinde karşılaştırıldı.
Bulgular:  Tedavi  edilmemiş  ratlarla  karşılaştırıldığında; 
EPO  ve  ALPA,  serum  glukoz  (p<0.05),  total  kolesterol 
(p<0.01), trigliserid (p<0.01), düşük yoğunluklu lipopro-
tein kolesterol (p<0.01) ve bir oksidatif stres belirteci olan 
tiobarbitürik  asit  reaktif  maddesi  düzeyinde  azalma)  ve 
yüksek yoğunluklu lipoprotein kolesterol (p<0.05 ve total 
antioksidan kapasitede (p<0.05 artışa neden oldu. Kombi-
nasyon tedavisi ile artmış pozitif etki gözlendi.
Sonuç: Bu çalışma EPO ve ALPA’nın özelikle birlikte kulla-
nıldığında glisemik kontrol, lipid bozuklukları ve antioksi-
dan kapasiteyi düzelterek, bozulmuş periferik sinir fonksi-
yonlarını büyük ölçüde iyileştireceğini düşündürmektedir. 
Klin Deney Ar Derg 2011; 2 (3): 245-253.
Anahtar kelimeler: Diabetik periferik nöropati, akşamse-
fası yağı, oksidatif stres, alfa lipoik asit
ABSTRACT
Objectives: Diabetic polyneuropathy is a serious compli-
cation of diabetes mellitus and the most frequent neu-
ropathy worldwide. Evening primrose oil (EPO) is rich in 
omega-6  essential  fatty  acid  component  and  gamma-
linolenic acid. Alpha lipoic acid (ALPA) has a protective 
effect against lipid peroxidation and helps in scavenging 
free radicals. Data regarding the effect of treatment with 
EPO on diabetic parameters and neuropathic manifesta-
tions are conflicting. This study aimed to determine the 
therapeutic efficacy of EPO and ALPA in correcting diabet-
ic parameters and functional and structural neuropathic 
manifestations in streptozotocin (STZ) induced diabetic 
rats.
Materials and methods: In this study, the effects of two 
week oral treatment with EPO (1.25 g/kg) was compared 
to that of ALPA (100 mg/kg) and insulin (2 IU/day), utilized 
singly or in combination.
Results: Compared with untreated diabetic rats, EPO and 
ALPA  resulted  in  reduction  of  serum  levels  of  glucose 
(p<0.05), total cholesterol (p<0.01), triglycerides (p<0.01), 
low density lipoprotein cholesterol (p<0.01), thiobarbitu-
ric acid reactive substance (a marker of oxidative stress) 
(p<0.05), and increased in levels of high density lipopro-
tein  cholesterol  (p<0.05)  and  total  antioxidant  capac-
ity (p<0.05). Enhanced positive effect was observed with 
combination therapy.
Conclusion: This work indicates that EPO and ALPA, par-
ticularly  when  used  in  combination,  improve  glycemic 
control, lipid abnormalities and antioxidant capacity, thus 
restore the impaired functional properties of peripheral 
nerves to a great extent. J Clin Exp Invest 2011; 2 (3): 245-
253.
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INTRODUCTION
Diabetes  mellitus  (DM)  is  often  associated  with 
neuropathic, cardiovascular, retinal and renal com-
plications. Evidence from several studies indicated 
that the prevalence rates of diabetic complications 
are  proportionately  related  to  the  magnitude  and 
duration  of  antecedent  hyperglycemia.1  Diabetic 
neuropathy  (DN)  is  a  common  complication  of 
DM. Results from animal and human studies in-
dicate that DN is a highly dynamic disorder; both 
degeneration and regeneration are present simulta-
neously. However, over time, the balance between 
degeneration and regeneration shifts toward more 
degeneration.2 Schwann cells and myelin forming 
cells of peripheral nerves are important in the regen-
erative process. These cells are impaired in DM as a 
result of hyperglycemia, hypoxia, oxidative stress3 
and loss of regenerative capacity of nerve fibers.4 
Several potential mechanisms are suggested as un-
derlying  causes  of  diabetic  microangiopathy  and 
neuropathy, which include: a) abnormal fatty acid 
metabolism (particularly the lower ratio of desatu-
ration of linoleic acid to gamma-linolenic acid)5, 
b)  abnormal  intracellular  metabolism  as  changes 
in peripheral nerve polyol metabolism, c) changes 
in Na+-K+- exchanging ATPase activity, d) deple-
tion of myo-inositol6, e) disruption of prostaglandin 
to thromboxane A2 ratio in favor of vasoconstric-
tion together with increase in platelet aggregation7, 
f) reduction of nerve blood flow and hypoxia8, g) 
impairment of cellular scavenging activity against 
oxidative stress9, h) decrease in specific isoforms of 
protein kinase (PKC)10, and i) loss of growth factor 
systems.11 As a result, number of agents have been 
experimentally investigated and showed some abil-
ity to prevent or reverse diabetes-induced chang-
es.  These  agents  include:  myo-inositol12,  aldose, 
reductase  inhibitors13,  aminoguanidine,14  nerve 
growth factor,15,16 antioxidants17-20 and nutrients rich 
in polyphenolic antioxidants (such as green tea, gar-
lic, olive oil and ginger).21
Evening primrose oil (EPO) is one of the most 
widely used herbal medicines in various parts of the 
world. EPO is extracted from the seeds of Oeno-
thera biennis. It is found in fields and roadsides in 
the United States and Canada.22,23 EPO has attracted 
attention as a medicinal plant as the oil of its seeds 
contains  high  concentrations  of  gamma-linoleic 
acid (GLA). EPO demonstrates therapeutic efficacy 
in some conditions like eczema, asthma, rheumatoid 
arthritis, breast problems and metabolic disorders.24-
27 EPO is a rich source of the omega-6 essential 
fatty acids such as GLA (a precursor of prostaglan-
din E1) and linoleic acid (LA). GLA and LA are 
essential components of myelin and neuronal cell 
membrane. In DM, the first step in the conversion 
of LA to GLA is disturbed leading to shortage of 
GLA and its metabolites as prostaglandins (PGs) 
and prostacyclin.27-29
Alpha lipoic acid (ALPA) has a protective ef-
fect against lipid peroxidation.30 ALPA may have a 
direct scavenging activity on free radicals. It may 
enhance the activity of other natural antioxidants 
and  antioxidant  enzymes  in  tissues  and  periph-
eral nerves such as reduced glutathione, vitamin C 
and vitamin E, catalase and superoxide dismutase 
(SOD).31-36
Data regarding the effects of EPO on glyce-
mic control, lipid profile and manifestations of pe-
ripheral  neuropathy  are  controversial  and  poorly 
understood.37-40 Here, we evaluated the effects of 
EPO, ALPA and insulin (used singly or in combina-
tion) on some diabetic parameters [as blood glucose 
level, lipid profile {total cholesterol (TC), triglyc-
erides (TG), low (LDL) and high density (HDL) 
lipoprotein cholesterol}, nitrate (an end product of 
nitric oxide oxidation), thiobarbituric acid reactive 
substances (TBARS), an indicator of lipid peroxi-
dation, and total antioxidant capacity (TAOC), an 
indicator of antioxidant reserve] and electrophysi-
ological manifestations associated with DN.
MATERIALS AND METHODS
Experimental design
This study was conducted on adult male strepto-
zotocin  (STZ)  induced  rats. Their  weight  ranged 
between 200-250 grams. The experiment was con-
ducted in accordance with international standards 
on animal welfare as well as being compliant with 
local and national regulations of practice for the care 
and use of animals for scientific purposes. Adequate 
measures were taken to minimize pain or discom-
fort. The protocol of this study was approved by the 
institutional animal experimentation ethics commit-
tee of Assiut University, Assiut, Egypt.
Rats were divided into the following groups; 
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control rats, 2) Group 2: non-diabetic rats treated 
orally with EPO, 3) Group 3: untreated STZ induced 
diabetic rats, 4) Group 4: STZ induced diabetic rats 
treated orally with EPO, 5) Group 5: STZ induced 
diabetic rats treated orally with ALPA, 6) Group 6: 
STZ induced diabetic rats treated orally with EPO 
and ALPA in similar doses as groups 4 and 5, 7) 
Group  7:  STZ  induced  diabetic  rats  treated  with 
subcutaneous (s.c) insulin, and 8) Group 8: STZ in-
duced diabetic rats treated with EPO and insulin.
Diabetes was induced by single intraperitoneal 
(i.p.) injection of STZ (Sigma chemical Co., USA) 
in a dose of 65 mg/kg and freshly dissolved in ster-
ile 0.9% saline solution. The non-diabetic control 
rats were injected with the same volume of sterile 
0.9% saline solution. Blood glucose concentration 
was determined 72 hours after STZ injection. The 
diabetic rats included in the study had blood glucose 
concentrations >13.89 mmol/L. Diabetic rats were 
left untreated for 6 weeks. This period is enough for 
the  development  of  diabetic  complications.41 The 
tested substances were then given to the rats by gav-
age for 2 weeks. EPO (Pharco for Pharmaceuticals 
& Medical Application Company, Egypt) was giv-
en orally in a dose of 1.25 g/kg daily. ALPA (EVA 
Pharm for Pharmaceuticals & Medical Application 
Company, Egypt) was given orally in a dose of 100 
mg/kg  daily.33  Insulin  (Mixtard  30HM,  Biphasic 
Isophane Insulin Injection 30/70) (Biosynthetic Hu-
man Insulin, Novo Nordisk, Denmark) was given 
subcutaneously (s.c.) in a dose of 2 IU daily.42
From all groups of rats, blood collection was 
done twice: after 6 weeks of induction of DM and 
after 2 weeks treatment with the tested substances 
(or 8 weeks after induction of DM). Blood sampling 
was done after a period of fasting for determina-
tion  of  the  following  biochemical  parameters:  1) 
The blood glucose level was determined using en-
zymatic colorimetric method kit supplied by Roche 
diagnostics, (GmbH, D-68298 Mannheim, USA)43; 
2) The serum lipid profile (TC, TG, LDL and HDL) 
was determined using enzymatic colorimetric kits 
supplied by Roche diagnostics, (GmbH, D-68298 
Mannheim, USA).44-46 LDL was calculated using the 
difference between TC and HDL.46 For glucose and 
lipids, the absorbance of the standard substance and 
blank was read at 500 nm using a spectrophotome-
ter (Pharmacic LKB Ultraspec Plus, England, Cam-
bridge), 3) Nitrate (one of the stable and non vola-
tile end-products of nitric oxide or NO oxidation) 
was determined using Griess reagent (Biochem for 
laboratory fine chemicals, USA)47, 4) Thiobarbituric 
acid reactive substance (TBARS) was determined 
colorimetrically (MP Biomedicals, Inc., France),48 
and 5) TAOC was determined (MP Biomedicals, 
Inc.,  France)  spectrophotometrically  (Pharmacic 
LKB Ultraspec Plus, England, Cambridge).49 Blood 
samples were kept at -20oC until the time of analy-
sis.
Clinical  and  electrophysiological  manifesta-
tions of DN were also assessed twice: after 6 weeks 
of induction of DM and after 2 weeks treatment 
with the tested substances (or 8 weeks after induc-
tion of DM) as follow: a) thermal and mechani-
cal pain was determined using hot plate test (Ugo 
basile biological research apparatus, Model 24780, 
Comerio-Va-Italy) by measuring the latency to ther-
mal threshold for each rat50, b) the nociceptive me-
chanical threshold was determined using the Paw 
pressure test (biological research apparatus, Model 
24880, Comerio-Va-Italy)51, c) motor coordination 
was determined using the rotarod test 52 (Treadmill 
for Rats 7700, Ugo basile biological research ap-
paratus, Comerio-Va-Itally) , and d) Nerve conduc-
tion velocity (NCV) was determined for the sciatic 
nerve using an invasive procedure in a temperature 
controlled environment29 as follow:
Rats were anesthetized with an i.p. injection of 
urethane dissolved in saline in a dose of 1-1.5 g/
kg. The sciatic nerve in the right leg was exposed 
at three sites. The two proximal (stimulating) sites 
were located near the sciatic notch (1st) and at ~15 
mm distal (2nd), and the distal (recording) or 3rd 
site was located at the distal end of the tibial nerve 
above the foot. The stimulating and recording elec-
trodes were placed directly under the sciatic nerve. 
The nerve was bathed in paraffin and maintained 
at 37°C under radiant heat. The sciatic nerve was 
stimulated by monophasic voltage pulses delivered 
directly to the nerve at 20% above threshold for the 
myelinated A-fibers. The evoked potentials were re-
corded using Harvard Universal Oscillograph (se-
rial No.400, England). Action potentials from both 
stimulating sites were averaged six to eight times. 
Following  NCV  recordings,  sutures  were  placed 
around the sciatic nerve at the sites of the stimulat-
ing electrodes. NCV was calculated by dividing the 
distance of nerve segment between the two stimulat-S. A. Hamed et al. Evening primrose oil in diabetic neuropathy 248
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ing sites measured in millimeters by the difference 
between proximal and distal latencies measured in 
milliseconds.
Statistical Analysis
Statistical Science for Social Package (SPSS Inc, 
USA) software computer program version 10 was 
used for data analysis. Data were presented as mean 
± S.E.M (standard error of mean). One-way ANOVA 
was used to provide information on whether there is 
a main effect of treatment. LSD was used to deter-
mine whether there are differences between specific 
treatment groups. LSD comparisons were corrected 
for multiple comparisons. For all tests, a probability 
(P) < 0.05 was considered significant.
RESULTS
STZ induced diabetic rats demonstrated increase in 
blood glucose level (>13.89 mmol/L) at 72 hours 
compared to that of non-diabetic control rats. Glu-
cose level remained higher (p<0.001) till the end of 
the experiment. STZ induced diabetic rats demon-
strated increase in serum levels of TC (p<0.001), TG 
(p<0.01), LDL-c (p<0.01) and TBARS (p<0.001) 
and decrease in serum levels of HDL-c (p<0.001), 
nitrate (p<0.001) and TAOC (p<0.001). Treatment of 
non-diabetic rats with EPO did not result in changes 
in serum levels of glucose, TC, TG, LDL, HDL, ni-
trate, TBARS and TAOC (Figures 1 and 2).
Compared to untreated STZ induced diabetic 
rats, diabetic rats treated with EPO, ALPA and in-
sulin demonstrated decrease in the serum levels of 
blood glucose (p<0.05, p<0.05, p<0.001 respective-
ly), TC (p<0.01 for all), TG (p<0.01 for all), LDL-c 
(p<0.05 for all) and TBARS (p<0.05 for all), and 
increase in the levels of HDL-c (p<0.01, p<0.01, 
p<0.05  respectively),  nitrate  (p<0.05  for  all)  and 
TAOC (p<0.05 for all) (Figures 1 and 2).
Compared to non-diabetic control rats, the un-
treated diabetic rats demonstrated manifestations of 
peripheral neuropathy in the form of decease in hot 
plate latency (p<0.001), mechanical pain threshold 
(p<0.001), the time spent on rotarod (p<0.01) and 
decease in NCV of sciatic nerve (p<0.01). Diabetic 
rats treated with EPO, ALPA and insulin showed a 
significant increase in hot plate latency (p<0.05 for 
all), mechanical pain threshold (p<0.05 for all), the 
time spent on rotarod (p<0.05 for all) and NCV of 
sciatic nerve (p<0.05 for all) (Figure 1 and Table 
1).
Comparing  combination  treatment  with  EPO 
and ALPA or EPO and insulin to single treatment 
with  either  ALPA  or  insulin,  combination  treat-
ment resulted in more decrease in the serum lev-
els of blood glucose (p<0.05 for both), TC (p<0.01 
for both), TG (p<0.01 for both), LDL-c (p<0.01 for 
both) and TBARS (p<0.01 for both), and more in-
crease in the levels of nitrate (p<0.05 for both) and 
TAOC (p<0.05 for both), more improvement in hot 
plate latency (p<0.01 for both) and more increase in 
mechanical pain threshold (p<0.01 for both) (Figure 
1 and 2, Table 1).
Table 1. Effect of different treatments on clinical and electrophysiological parameters
Group Hot plate
 latency (S)
Mechanical pain
 threshold (gm)
Time spent in
 rotarods (S)
NCV (m/s)
1 Control non-diabetic rats 10.6 ± 0.96 128.9 ± 6.2 121.20 ± 3.73 53.64 ± 2.35
2 Non-diabetic rats treated with EPO 11.33 ± 0.81 129.5 ± 4.5 122.00 ± 3.64 55.13 ± 2.35
3 STZ-diabetic rats 6.25 ± 0.59○○○ 89.5 ± 7.3○○○ 85.4 ± 4.91○○ 41.40 ± 2.16○○
4 STZ-diabetic rats treated with EPO 9.13 ± 0.66* 111.9 ± 6.3* 107.40 ± 5.68* 49.96 ± 2.15*
5 STZ-diabetic rats treated with ALPA 9.27 ± 0.81* 113.5 ± 4.7* 107.90 ± 5.50* 50.06 ± 2.60*
6 STZ-diabetic rats treated with EPO and ALPA 10.43 ± 0.74** 150.4 ± 4.7***,‡‡ 109.20 ± 5.54* 51.74 ± 1.76**
7 STZ-diabetic rats treated with insulin 8.82  ± 0.55* 110.7 ± 5.1* 105.70 ± 6.96* 51.25 ± 1.65*
8 STZ-diabetic rats treated with EPO and insulin 9.73 ± 0.65** 147.1 ± 4.4***,‡‡ 107.80 ± 5.7* 49.67 ± 1.94**
Data are expressed as mean ± S.E.M
Group 3: STZ-diabetic rats (6 weeks after induction of DM); Groups 4-8: STZ-diabetic rats (after 2 weeks treatment)
STZ, Streptozotocin; EPO, primrose oil; ALPA, alpha lipoic acid; NCV, nerve conduction velocity; S: second; m/s: meter/
second 
○○P<0.01, ○○○P<0.001 compared to non diabetic control rat; *P<0.05, **P<0.01, ***P<0.001 compared to STZ-diabetic 
control rats; ‡P<0.05, ‡‡P<0.01, compared to STZ-diabetic rats treated with either EPO or ALPA aloneS. A. Hamed et al. Evening primrose oil in diabetic neuropathy 249
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Figure 1. Effect of different treatments on serum biochemistry
Figure 2. Effect of different treatments on lipid profileS. A. Hamed et al. Evening primrose oil in diabetic neuropathy 250
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DISCUSSION
The results of this study confirmed that EPO, ALPA 
and insulin were able to reverse neuropathic mani-
festations towards normal levels which might be due 
to: 1) correction of hyperglycemia 17,53, 2) correction 
of lipid profile54,55, 3) induction of vasodilatation in 
tissues55,56, and 4) antioxidant or free radical scav-
enging activity.57
STZ induces damage of pancreatic cells result-
ing in hyperglycemia, hypoxia and oxidative stress. 
STZ  increases  glycation  of  collagen  and  plasma 
proteins.  STZ  enhances  auto-oxidative  reactions 
of sugars and aggravate damage to both lipids and 
proteins in the circulation resulting in hypercholes-
terolemia or dyslipidemia.54,55 However, some stud-
ies reported that in STZ induced diabetic rats, EPO 
was able to restore NCV of peripheral nerves to its 
normal levels without reduction of hyperglycemia 
suggesting a neuroprotective effect.37,38 In contrast, 
others reported that EPO was unable to reverse vari-
ous lipid abnormalities induced by DM58,59 or even 
it could increase the levels of TC and TG and reduce 
the levels of HDL.54 The conflicting results of dif-
ferent studies could be explained by the differences 
in materials and methods, age of the tested animals, 
duration  of  drug  treatments  and  their  prescribed 
doses.
This study and others showed that EPO, ALPA 
or insulin were able to increase the levels of nitrate 
impaired by STZ.60 Nitrate is an end product of ni-
tric oxide (NO) oxidation.55 At low physiological 
levels,  NO  modulates  vascular  tone  in  a  similar 
manner to endothelial-dependent relaxing factor. In 
addition, NO has a potent free radical scavenging 
activity.61 Under physiological conditions, nitric ox-
ide synthase (NOS), a rate forming enzyme of NO, 
is present in pancreatic β-cells and is involved in 
the release of insulin.62 In DM, disturbance in lev-
els of NO and NOS have been suggested to impair 
endothelium-dependent vasodilatation of pancreatic 
vascular beds and insulin production resulting in 
oxidative stress and hyperglycemia.63
In experimental models of DM, the increase in 
levels of lipid peroxides, free radicals and oxidative 
stress and the decrease in levels of antioxidant re-
serve, cause oxidation of polyunsaturated fatty ac-
ids (PUFAs) which are embedded in the cell mem-
brane.64  This  causes  damage  of  pancreatic  cells, 
hyperglycemia and DM.65,66 We and others showed 
that EPO, ALPA and insulin are able to reduce lipid 
peroxidation and enhance the total antioxidant sta-
tus of the body as evidenced by reduction in levels 
of TBARS67 and increase in levels of TAOC ob-
served in this study as compared to pre-treatment 
levels.54,68 TBARS is formed during non-enzymatic 
auto-oxidation of PUFAs. It is an indicator of lipid 
peroxidation and oxidative stress burden.69 TAOC 
measures the collective activities of wide range of 
antioxidants such as vitamin E, vitamin C, vitamin 
A, uric acid, glutathione and antioxidant enzymes 
including glutathione reductase (GSH.R), glutathi-
one peroxidase (GSH.Px) and superoxide dismutase 
(SOD).69
The results of this study indicate that combi-
nation treatment with EPO and ALPA or EPO and 
insulin is more effective than singular treatment in 
improvement of biochemical parameters associated 
with DM and more improvement of manifestations 
of peripheral neuropathy induced by DM. In gen-
eral, this therapeutic effectiveness could be due to 
additive effect, synergistic effect or both. Additive 
means an augmented net effect through action on 
the same pathway, while synergism means an aug-
mented net effect through action on two different 
pathways.
In conclusion, EPO and ALPA are effective in 
lowering lipid and hemostatic risk factors in STZ 
induced DN. The therapeutic effects of EPO seemed 
similar to ALPA and augmented by combined ad-
ministration with ALPA or insulin. However, wheth-
er the beneficiary results of combination treatment 
on the levels of blood glucose, lipids, nitrate, oxida-
tive stress and antioxidant markers are due to addi-
tive or synergistic effect or both, are still unknown. 
Continuing research efforts are needed to explore 
the exact mechanisms of EPO in DN.
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